Report Detail

Pharma & Healthcare Global Gastrointestinal Stromal Tumor (GIST) Drug Market Insights, Forecast to 2025

  • RnM3061422
  • |
  • 05 March, 2019
  • |
  • Global
  • |
  • 129 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

The global Gastrointestinal Stromal Tumor (GIST) Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Gastrointestinal Stromal Tumor (GIST) Drug market based on company, product type, end user and key regions.

This report studies the global market size of Gastrointestinal Stromal Tumor (GIST) Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Gastrointestinal Stromal Tumor (GIST) Drug in these regions.
This research report categorizes the global Gastrointestinal Stromal Tumor (GIST) Drug market by top players/brands, region, type and end user. This report also studies the global Gastrointestinal Stromal Tumor (GIST) Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Ariad Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Boston Biomedical, Inc.
Calithera Biosciences, Inc.
Chipscreen Biosciences Ltd
Deciphera Pharmaceuticals, LLC
F. Hoffmann-La Roche Ltd.
Horizon Pharma Plc
Immunicum AB
Jiangsu Hengrui Medicine Co., Ltd.
Kolltan Pharmaceuticals, Inc.
Natco Pharma Limited
Nerviano Medical Sciences S.r.l.
Novartis AG
Omeros Corporation

Market size by Product
Amcasertib
Anagrelide hydrochloride CR
APG-1351
Binimetinib
Others
Market size by End User
Clinic
Hospital
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Gastrointestinal Stromal Tumor (GIST) Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Gastrointestinal Stromal Tumor (GIST) Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Gastrointestinal Stromal Tumor (GIST) Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Gastrointestinal Stromal Tumor (GIST) Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Gastrointestinal Stromal Tumor (GIST) Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Gastrointestinal Stromal Tumor (GIST) Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Table of Contents

    1 Study Coverage

    • 1.1 Gastrointestinal Stromal Tumor (GIST) Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size Growth Rate by Product
      • 1.4.2 Amcasertib
      • 1.4.3 Anagrelide hydrochloride CR
      • 1.4.4 APG-1351
      • 1.4.5 Binimetinib
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size Growth Rate by End User
      • 1.5.2 Clinic
      • 1.5.3 Hospital
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size
      • 2.1.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue 2014-2025
      • 2.1.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales 2014-2025
    • 2.2 Gastrointestinal Stromal Tumor (GIST) Drug Growth Rate by Regions
      • 2.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Regions
      • 2.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Gastrointestinal Stromal Tumor (GIST) Drug Sales by Manufacturers
      • 3.1.1 Gastrointestinal Stromal Tumor (GIST) Drug Sales by Manufacturers
      • 3.1.2 Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Manufacturers
      • 3.2.1 Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Gastrointestinal Stromal Tumor (GIST) Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Gastrointestinal Stromal Tumor (GIST) Drug Price by Manufacturers
    • 3.4 Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Gastrointestinal Stromal Tumor (GIST) Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Gastrointestinal Stromal Tumor (GIST) Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Gastrointestinal Stromal Tumor (GIST) Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Product
    • 4.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Product
    • 4.3 Gastrointestinal Stromal Tumor (GIST) Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Gastrointestinal Stromal Tumor (GIST) Drug by Countries
      • 6.1.1 North America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries
      • 6.1.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Gastrointestinal Stromal Tumor (GIST) Drug by Product
    • 6.3 North America Gastrointestinal Stromal Tumor (GIST) Drug by End User

    7 Europe

    • 7.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug by Countries
      • 7.1.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries
      • 7.1.2 Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Gastrointestinal Stromal Tumor (GIST) Drug by Product
    • 7.3 Europe Gastrointestinal Stromal Tumor (GIST) Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug by Countries
      • 8.1.1 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries
      • 8.1.2 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug by Product
    • 8.3 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug by End User

    9 Central & South America

    • 9.1 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug by Countries
      • 9.1.1 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries
      • 9.1.2 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug by Product
    • 9.3 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug by Countries
      • 10.1.1 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries
      • 10.1.2 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug by Product
    • 10.3 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug by End User

    11 Company Profiles

    • 11.1 Ariad Pharmaceuticals, Inc.
      • 11.1.1 Ariad Pharmaceuticals, Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.1.5 Ariad Pharmaceuticals, Inc. Recent Development
    • 11.2 Arog Pharmaceuticals, Inc.
      • 11.2.1 Arog Pharmaceuticals, Inc. Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.2.5 Arog Pharmaceuticals, Inc. Recent Development
    • 11.3 Array BioPharma Inc.
      • 11.3.1 Array BioPharma Inc. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.3.5 Array BioPharma Inc. Recent Development
    • 11.4 Astex Pharmaceuticals, Inc.
      • 11.4.1 Astex Pharmaceuticals, Inc. Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.4.5 Astex Pharmaceuticals, Inc. Recent Development
    • 11.5 Blueprint Medicines Corporation
      • 11.5.1 Blueprint Medicines Corporation Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.5.5 Blueprint Medicines Corporation Recent Development
    • 11.6 Boston Biomedical, Inc.
      • 11.6.1 Boston Biomedical, Inc. Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.6.5 Boston Biomedical, Inc. Recent Development
    • 11.7 Calithera Biosciences, Inc.
      • 11.7.1 Calithera Biosciences, Inc. Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.7.5 Calithera Biosciences, Inc. Recent Development
    • 11.8 Chipscreen Biosciences Ltd
      • 11.8.1 Chipscreen Biosciences Ltd Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.8.5 Chipscreen Biosciences Ltd Recent Development
    • 11.9 Deciphera Pharmaceuticals, LLC
      • 11.9.1 Deciphera Pharmaceuticals, LLC Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.9.5 Deciphera Pharmaceuticals, LLC Recent Development
    • 11.10 F. Hoffmann-La Roche Ltd.
      • 11.10.1 F. Hoffmann-La Roche Ltd. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.10.5 F. Hoffmann-La Roche Ltd. Recent Development
    • 11.11 Horizon Pharma Plc
    • 11.12 Immunicum AB
    • 11.13 Jiangsu Hengrui Medicine Co., Ltd.
    • 11.14 Kolltan Pharmaceuticals, Inc.
    • 11.15 Natco Pharma Limited
    • 11.16 Nerviano Medical Sciences S.r.l.
    • 11.17 Novartis AG
    • 11.18 Omeros Corporation

    12 Future Forecast

    • 12.1 Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast by Regions
      • 12.1.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast by Product
      • 12.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Product 2019-2025
    • 12.3 Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast by End User
    • 12.4 North America Gastrointestinal Stromal Tumor (GIST) Drug Forecast
    • 12.5 Europe Gastrointestinal Stromal Tumor (GIST) Drug Forecast
    • 12.6 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Forecast
    • 12.7 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug Forecast
    • 12.8 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Gastrointestinal Stromal Tumor (GIST) Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Summary:
      Get latest Market Research Reports on Gastrointestinal Stromal Tumor (GIST) Drug . Industry analysis & Market Report on Gastrointestinal Stromal Tumor (GIST) Drug is a syndicated market report, published as Global Gastrointestinal Stromal Tumor (GIST) Drug Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Gastrointestinal Stromal Tumor (GIST) Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,120.00
      4,680.00
      6,240.00
      3,642.60
      5,463.90
      7,285.20
      613,587.00
      920,380.50
      1,227,174.00
      325,221.00
      487,831.50
      650,442.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report